Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Beleut, Manfred ^a,d   Zimmermann, Philip ^b   Baudis, Michael ^c   Bruni, Nicole ^b   Bühlmann, Peter ^b   Laule, Oliver ^b   Luu, Van Duc ^a   Gruissem, Wilhelm ^b   Schraml, Peter ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d PAREQ Research AG   (Switzerland)

Author keywords

DNA microarray; Outcome; RCC subgroups; SNP array; Tissue microarray

Indexed keywords

ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MAPPING; GENETIC ASSOCIATION; GENOME ANALYSIS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TISSUE MICROARRAY;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84868371027     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-310     Document Type: Article

References (50)

1. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006, 33(5):527-533. 10.1053/j.seminoncol.2006.06.010, 17045081.
2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, IARC Press, Lyon.
3. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009, 56(4):636-643. 10.1016/j.eururo.2009.06.036, 19595500.
4. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260(5112):1317-1320. 10.1126/science.8493574, 8493574.
5. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69(11):4674-4681. 10.1158/0008-5472.CAN-09-0146, 2745239, 19470766.
6. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463(7279):360-363. 10.1038/nature08672, 2820242, 20054297.
7. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001, 61(19):7277-7281.
8. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16(1):68-73. 10.1038/ng0597-68, 9140397.
9. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 1997, 181(2):136-139. 10.1002/(SICI)1096-9896(199702)181:2<136::AID-PATH766>3.0.CO;2-2, 9120715.
10. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. Cancer Res 2011, 71(16):5500-5511. 10.1158/0008-5472.CAN-11-0757, 21715564.
11. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal 2008, 1(24):pe30. 10.1126/scisignal.124pe30, 18560019.
12. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18(14):2343-2350. 10.1038/sj.onc.1202547, 10327054.
13. Morris MR, Maina E, Morgan NV, Gentle D, Astuti D, Moch H, Kishida T, Yao M, Schraml P, Richards FM, et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 2004, 57(7):706-711. 10.1136/jcp.2003.011767, 1770369, 15220362.
14. Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, Ludlow J, Knapp R, Giraud S, Richard S, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003, 63(15):4583-4587.
15. Boer JM, Huber WK, Sultmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Fuzesi L, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001, 11(11):1861-1870. 311168, 11691851.
16. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005, 11(16):5730-5739. 10.1158/1078-0432.CCR-04-2225, 16115910.
17. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005, 11(14):5128-5139. 10.1158/1078-0432.CCR-05-0073, 16033827.
18. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003, 3:31. 10.1186/1471-2407-3-31, 317310, 14641932.
19. Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, Hornsby CD, Yang WL, Petros JA, Issa MM, Pattaras JG, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 2005, 7(2):206-218. 10.1016/S1525-1578(10)60547-8, 1867531, 15858144.
20. Skubitz KM, Skubitz AP. Differential gene expression in renal cell cancer. J Lab Clin Meds 2002, 140(1):52-64.
21. Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Fuzesi L, Poustka A. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 2005, 11(2 Pt 1):646-655.
22. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001, 98(17):9754-9759. 10.1073/pnas.171209998, 55525, 11493696.
23. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003, 22(43):6810-6818. 10.1038/sj.onc.1206869, 14555994.
24. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 2003, 100(12):6958-6963. 10.1073/pnas.1131754100, 165812, 12777628.
25. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001, 158(5):1639-1651. 10.1016/S0002-9440(10)64120-X, 1891957, 11337362.
26. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer 2010, 1(2):152-163. 10.1177/1947601909359929, 2943630,2943630, 20871783.
27. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
28. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J. TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
29. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
30. Hruz T, Laule O, Szabo G, Wessendorp F, Bleuler S, Oertle L, Widmayer P, Gruissem W, Zimmermann P. Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics 2008, 2008:420747. 2777001, 19956698.
31. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 2010, 38(Database issue):D204-D210. 2808919, 20015972.
32. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci 2003, 43(6):1947-1958. 10.1021/ci034160g, 14632445.
33. Venables WN, Ripley BD. Modern Applied Statistics with S 2002, Springer, New York, 4.
34. Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009, 25(17):2149-2156. 10.1093/bioinformatics/btp371, 2734319, 19535535.
35. Bengtsson H, Ray A, Spellman P, Speed TP. A single-sample method for normalizing and combining full-resolution copy numbers from multiple platforms, labs and analysis methods. Bioinformatics 2009, 25(7):861-867. 10.1093/bioinformatics/btp074, 2660872, 19193730.
36. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23(6):657-663. 10.1093/bioinformatics/btl646, 17234643.
37. Baudis M, Cleary ML. Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001, 17(12):1228-1229. 10.1093/bioinformatics/17.12.1228, 11751233.
38. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001, 25(3):275-284. 10.1097/00000478-200103000-00001, 11224597.
39. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
40. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, Moch H. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196(2):186-193. 10.1002/path.1034, 11793370.
41. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 2007, 7:226. 10.1186/1471-2407-7-226, 2225423, 18088415.
42. Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000, 60(16):4519-4525.
43. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010, 7(5):277-288. 10.1038/nrclinonc.2010.42, 20368728.
44. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007, 356(2):185-187. 10.1056/NEJMe068263, 17215538.
45. Grabmaier K, AdW MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23(33):5624-5631. 10.1038/sj.onc.1207764, 15184875.
46. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425(6955):307-311. 10.1038/nature01874, 13679920.
47. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D. An integrated approach to uncover drivers of cancer. Cell 2010, 143(6):1005-1017. 10.1016/j.cell.2010.11.013, 3013278, 21129771.
48. Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One 2010, 5(3):e9651. 10.1371/journal.pone.0009651, 2836370, 20300172.
49. Huret JL, Senon S, Bernheim A, Dessen P. An Atlas on genes and chromosomes in oncology and haematology. Cell Mol Biol (Noisy-le-Grand) 2004, 50(7):805-807.
50. Poste G. Bring on the biomarkers. Nature 2011, 469(7329):156-157. 10.1038/469156a, 21228852.